Medicines availability for non-communicable diseases: The case for standardized monitoring

Globalization and Health

Volumn 11, Issue 1, 2015, Pages

  Robertson, Jane ^a,b   Macé, Cécile ^a   Forte, Gilles ^a   de Joncheere, Kees ^a   Beran, David ^c,d  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Availability; Essential medicines; Monitoring; Non communicable diseases

Indexed keywords

ATENOLOL; BENDROFLUMETHIAZIDE; CAPTOPRIL; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; INSULIN; LISINOPRIL; METFORMIN; NIFEDIPINE; PROPRANOLOL; THIAZIDE DIURETIC AGENT; PRESCRIPTION DRUG;

DIABETES; DISEASE TREATMENT; HYPERTENSION; MEDICINE; MONITORING; PUBLIC ACCESS;

ARTICLE; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG MONITORING; FAITH BASED ORGANIZATION FACILITY; HEALTH CARE AVAILABILITY; HEALTH CARE FACILITY; HEALTH CENTER; HEALTH SERVICE; HOSPITAL; HUMAN; HYPERTENSION; MEDICINE AVAILABILITY; NON COMMUNICABLE DISEASE; PHARMACY; PRIORITY JOURNAL; PRIVATE HOSPITAL; PUBLIC HOSPITAL; TANZANIA; URBAN RURAL DIFFERENCE; CHRONIC DISEASE; HEALTH; ORGANIZATION AND MANAGEMENT; SUPPLY AND DISTRIBUTION;

TANZANIA;

CHRONIC DISEASE; EFFICIENCY, ORGANIZATIONAL; GLOBAL HEALTH; HEALTH FACILITIES; HUMANS; PRESCRIPTION DRUGS; TANZANIA;

EID: 84929162373     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/s12992-015-0105-0     Document Type: Article

References (20)

1. World Health Organization. Key components of a well-functioning health system. Geneva: World Health Organization, 2010. [http://www.who.int/healthsystems/publications/hss_key/en/]
2. World Health Organization. The Selection and Use of Essential Medicines. Report of the WHO Expert Committee, 2013. Technical Report Series 985. [http://www.who.int/medicines/publications/essentialmeds_committeereports/en/]
3. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ. 2011;89:412-21.
4. Mendis S, Fukino K, Cameron A, Laing R, Filipe Jr A, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007;85:279-88.
5. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:240-9.
6. van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010;10:25.
7. UN General Assembly. Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. New York: United Nations General Assembly; 2012. Document No.: 66/2.
8. World Health Organization. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. Geneva: World Health Organization, 2013. [http://www.who.int/nmh/events/ncd_action_plan/en/]
9. World Health Organization. NCD Global Monitoring Framework: ensuring progress on noncommunicable diseases in countries. [http://www.who.int/nmh/global_monitoring_framework/en/]
10. World Health Organization. Implementation tools Package of Essential Noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Geneva: World Health Organization, 2013. [http://www.who.int/cardiovascular_diseases/publications/implementation_tools_WHO_PEN/en/]
11. Peck R, Mghamba J, Vanobberghen F, Kavishe B, Rugarabamu V, Smeeth L, et al. Preparedness of Tanzanian health facilities for outpatient primary care of hypertension and diabetes: a cross-sectional survey. Lancet Global Health. 2014;2:e285-92.
12. WHO/HAI. Measuring medicine prices, availability, affordability and price components. 2nd Edition. Geneva, Switzerland; 2008 [http://www.haiweb.org/medicineprices/manual/documents.html]
13. Ministry of Health and Social Welfare, Tanzania. Tanzania Service Availability and Readiness Assessment (2012). Final report July 2013. [http://www.ihi.or.tz/announ/availabilityandreadinessassessmentresultsannounced]
14. O'Neill K, Takane M, Sheffel A, Abou-Zahr C, Boerma T. Monitoring service delivery for universal health coverage: the Service Availability and Readiness Assessment. Bull World Health Organ. 2013;91:923-31.
15. Madden JM, Meza E, Ewen M, Laing RO, Stephens P, Ross-Degnan D. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica. 2010;27:291-9.
16. World Health Organization. WHO's Leadership Priorities. [http://www.who.int/about/who_reform/change_at_who/leadership_priorities/en/#.VUp0xfmqqko]
17. Beran D, Yudkin JS. Looking beyond the issue of access to insulin: what is needed for proper diabetes care in resource poor settings. Diabetes Res Clin Pract. 2010;88:217-21.
18. Adeloye D, Basquill C. Estimating the prevalence and awareness rates of hypertension in Africa: a systematic analysis. PLoS ONE. 2014;9(8):e104300.
19. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, et al. Priority actions for the non-communicable disease crisis. Lancet. 2011;377:1438-47.
20. World Health Organization 2014. Access to Medicines. Sixty-seventh World Health Assembly WHA67.22. [http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R22-en.pdf]